Age and Racial/Ethnic Differences in the Prevalence of Reported Symptoms in Human Immunodeficiency Virus-Infected Persons on Antiretroviral Therapy

Journal of Pain and Symptom Management

Volumn 38, Issue 2, 2009, Pages 197-207

  Silverberg, Michael J ^a,b   Jacobson, Lisa P ^a   French, Audrey L ^c   Witt, Mallory D ^d,e   Gange, Stephen J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b DIVISION OF RESEARCH   (United States)

^c Jr Hospital of Cook County   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

aging; Highly active antiretroviral therapy; race ethnicity; sex; symptoms

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; ARTICLE; CAUCASIAN; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ETHNICITY; FEMALE; GASTROINTESTINAL SYMPTOM; GROUPS BY AGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALAISE; MALE; METABOLIC DISORDER; MULTICENTER STUDY; NEUROLOGIC DISEASE; PARESTHESIA; PHYSICIAN; PREVALENCE; RACE DIFFERENCE; RISK FACTOR; SELF REPORT; SYMPTOM; TREATMENT DURATION;

ADULT; AGE FACTORS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; ETHNIC GROUPS; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; SEX FACTORS; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 67651167081     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2008.08.007     Document Type: Article

References (27)

1. Detels R., Munoz A., McFarlane G., et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 280 (1998) 1497-1503
2. Perez-Hoyos S., del Amo J., Muga R., et al. Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category. AIDS 17 (2003) 353-359
3. Porter K., Babiker A., Bhaskaran K., et al. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 362 (2003) 1267-1274
4. Silverberg M.J., Wegner S.A., Milazzo M.J., et al. Effectiveness of highly-active antiretroviral therapy by race/ethnicity. AIDS 20 (2006) 1531-1538
5. Tarwater P.M., Mellors J., Gore M.E., et al. Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts. Am J Epidemiol 154 (2001) 675-681
6. Mack K.A., and Ory M.G. AIDS and older Americans at the end of the twentieth century. J Acquir Immune Defic Syndr 33 Suppl 2 (2003) S68-S75
7. Espinoza L., Hall H.I., Campsmith M.L., and Lee L.M. Trends in HIV/AIDS diagnoses-33 states, 2001-2004. MMWR Morb Mortal Wkly Rep 54 (2005) 1149-1153
8. Tedaldi E.M., Absalon J., Thomas A.J., Shlay J.C., and van den Berg-Wolf M. Ethnicity, race, and gender. Differences in serious adverse events among participants in an antiretroviral initiation trial: results of CPCRA 058 (FIRST Study). J Acquir Immune Defic Syndr 47 (2008) 441-448
9. Bonfanti P., Valsecchi L., Parazzini F., et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. J Acquir Immune Defic Syndr 23 (2000) 236-245
10. Currier J.S., Spino C., Grimes J., et al. Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The AIDS Clinical Trials Group 175 Team. J Acquir Immune Defic Syndr 24 (2000) 316-324
11. Fellay J., Boubaker K., Ledergerber B., et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 358 (2001) 1322-1327
12. Lucas G.M., Chaisson R.E., and Moore R.D. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 131 (1999) 81-87
13. Moore R.D., Fortgang I., Keruly J., and Chaisson R.E. Adverse events from drug therapy for human immunodeficiency virus disease. Am J Med 101 (1996) 34-40
14. Silverberg M.J., Gore M.E., French A.L., et al. Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interagency HIV Study. Clin Infect Dis 39 (2004) 717-724
15. Zingmond D.S., Kilbourne A.M., Justice A.C., et al. Differences in symptom expression in older HIV-positive patients: the Veterans Aging Cohort 3 Site Study and HIV Cost and Service Utilization Study experience. J Acquir Immune Defic Syndr 33 Suppl 2 (2003) S84-S92
16. Skolasky R.L., Phair J., Detels R., et al. Thrush and fever as markers of immune competence in the era of highly active antiretroviral therapy. AIDS Res Hum Retroviruses 17 (2001) 1311-1316
17. Karus D., Raveis V.H., Alexander C., et al. Patient reports of symptoms and their treatment at three palliative care projects servicing individuals with HIV/AIDS. J Pain Symptom Manage 30 (2005) 408-417
18. Barkan S.E., Melnick S.L., Preston-Martin S., et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology 9 (1998) 117-125
19. Kaslow R.A., Ostrow D.G., Detels R., et al. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol 126 (1987) 310-318
20. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available from. http://aidsinfo.nih.gov/Guidelines/ Accessed March 9, 2009
21. Diggle P.J., Liang K.Y., and Zeger S.L. Analysis of longitudinal data (1995), Oxford University Press, New York, NY
22. Lichtenstein K.A., Ward D.J., Moorman A.C., et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 15 (2001) 1389-1398
23. Martinez E., Mocroft A., Garcia-Viejo M.A., et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 357 (2001) 592-598
24. Thiebaut R., Daucourt V., Mercie P., et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidemiologie Clinique du Syndrome d'Immunodeficience Acquise en Aquitaine. Clin Infect Dis 31 (2000) 1482-1487
25. Henderson M., Safa F., Easterbrook P., and Hotopf M. Fatigue among HIV-infected patients in the era of highly active antiretroviral therapy. HIV Med 6 (2005) 347-352
26. Sullivan P.S., and Dworkin M.S. Prevalence and correlates of fatigue among persons with HIV infection. J Pain Symptom Manage 25 (2003) 329-333
27. Reynolds N.R., and Neidig J.L. Characteristics of nausea reported by HIV-infected patients initiating combination antiretroviral regimens. Clin Nurs Res 11 (2002) 71-88